JCS/JPCPHS 2025 Guideline on Pulmonary Hypertension and Pulmonary Embolism/Deep Vein Thrombosis

Q: What is the clinical evidence from this study?

Study design: Review. Population: Pulmonary Hypertension, Pulmonary Embolism, and Deep Vein Thrombosis. Intervention: Clinical Guidelines.

Yuichi Tamura; Kenya Kusunose; Yugo Yamashita; Teiji Akagi; Masanori Atsukawa; Yoshihiro Fukumoto; Ayumi Goda; Shinya Goto; Masaru Hatano; Masataka Ikeda; Keiichi Ishida; Masaharu Kataoka; Masataka Kuwana; Hiromi Matsubara; Makoto Mo; Tetsutaro Nagaoka; Takeshi Ogo; Yoshinori Okada; Seiichiro Sakao; Hirofumi Sawada; Toshiro Shinke; Nobuhiro Tanabe; Norikazu Yamada; Hiroyuki Yamagishi; Shingo Yano; K Abe; Shiro Adachi; Kazuya Hosokawa; Nobutaka Ikeda; Takumi Inami; M Jinzaki; Masaru Kato; T Kitai; Shigetoyo Kogaki; Jun Koizumi; Yoshiteru Morio; Mari Nishizaki; Yoshito Ogihara; Keiko Ohta‐Ogo; Kunihiro Shigematsu; Koichiro Sugimura; Yudai Tamura; Yu Taniguchi; Ichizo Tsujino; K. Uchida; Takeshi Yamamoto; Atsushi Yao; Nobuhiro Yaoita; Noriaki Emoto; Hiroaki Kitaoka; Mashio Nakamura; Hitoshi Ogino; Toru Satoh; Hiroshi Watanabe; on behalf of the Japanese Circulation Society and Japanese Pulmonary Circulation and Pulmonary Hypertension Society Joint Working Group

doi:10.1253/circj.cj-25-1144

June 29, 2026Circulation JournalOpen Access

JCS/JPCPHS 2025 Guideline on Pulmonary Hypertension and Pulmonary Embolism/Deep Vein Thrombosis

View Full Paper

Ask AI

Bookmark

Share

Key Points

Consolidate and update clinical recommendations for the diagnosis, evaluation, and management of pulmonary hypertension, pulmonary embolism, and deep vein thrombosis into a single integrated framework.
Convened a joint working group from the Japanese Circulation Society and partner societies to synthesize evidence across pulmonary vascular disorders.
Integrated and updated three previous guidelines addressing pulmonary embolism/deep vein thrombosis, pulmonary hypertension, and balloon pulmonary angioplasty.
Defined post-capillary pulmonary hypertension as mPAP >20 mmHg and PAWP >15 mmHg, classified as isolated when PVR ≤2 Wood units and combined when PVR >2 Wood units.
Identified exercise pulmonary hypertension as an mPAP/CO slope >3 mmHg/L/min, while noting right heart catheterization carries a 1.1% serious adverse event rate and 0.055% procedure-related mortality.
Reported that ventilation-perfusion scintigraphy achieves a sensitivity of 90–100% and specificity of 94–100% for chronic thromboembolic pulmonary hypertension.

PICO

P

Population

Pulmonary Hypertension, Pulmonary Embolism, and Deep Vein Thrombosis

I

Intervention / Comparator

Clinical Guidelines

Implication

Adopt 2025 JCS/JPCPHS recommendations for PH and VTE management now; extends prior guidelines with updated expert consensus.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Tamura et al. (2026) conducted a review in Pulmonary Hypertension, Pulmonary Embolism, and Deep Vein Thrombosis. Clinical Guidelines was evaluated. The JCS/JPCPHS 2025 Guideline provides updated, comprehensive recommendations for the diagnosis, treatment, and prevention of pulmonary hypertension and venous thromboembolism.

synapsesocial.com/papers/6a45ff3c9ed134303130fb21 https://doi.org/10.1253/circj.cj-25-1144

View Full Paper

Ask AI

Bookmark

Share

JCS/JPCPHS 2025 Guideline on Pulmonary Hypertension and Pulmonary Embolism/Deep Vein Thrombosis

Key Points

PICO

Implication

Abstract

Discussion

Cite This Study

JCS/JPCPHS 2025 Guideline on Pulmonary Hypertension and Pulmonary Embolism/Deep Vein Thrombosis

Key Points

PICO

Implication

Abstract

Discussion

Cite This Study

Keep reading

Keep reading